C12N 2760/18733
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18733 (Use of viral protein as therapeutic agent other than vaccine) appears on 2 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 2
- Published applications
- 5
- Assignees
- 6
- Inventors
- 8
- Latest grant
- 18 Aug 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection11 Apr 2019US 2019/0105263 A1BioVentures, LLC
- Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection24 Mar 2016US 2016/0081918 A1Squarex, LLC
- Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection13 Aug 2015US 2015/0224067 A1Board of Trustees of the University of Arkansas
- Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection4 Mar 2010US 2010/0055132 A1
Most cited
By later US patents